Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$83,097.00+1.89%ETH$2,455.36+2.50%GOLD$4,138.20-0.11%OIL$98.47+0.66%
Smart Investors Daily
SID Premium
Bausch Health Companies Inc. logo

NYSE · BHC

Bausch Health Companies Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$6.42

Up+$0.10 (+1.58%)

Updated Oct 21, 2026, 7:06 AM

SID Score

6.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.6B
P/E ratio
7.19
Dividend yield
0.00%
52-week range
$4.33 – $8.00
Volume
2.03M
Avg. volume
2.36M

Price performance · BHC

BHC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 20, 2026

BHC closed at $6.42 after 21 trading sessions, up 10.50% for the selected period.

Last close
$6.42
Period change
+10.50%
Period low
$5.65
Period high
$6.42
Daily close
View OHLC price history
BHC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 20, 2026$6.42$6.54$6.36$6.422.03M
Oct 19, 2026$6.27$6.42$6.25$6.321.35M
Oct 16, 2026$6.35$6.385$6.20$6.302.19M
Oct 15, 2026$5.95$6.35$5.95$6.312.31M
Oct 14, 2026$5.89$6.05$5.85$5.891.75M
Oct 13, 2026$5.91$5.92$5.732$5.891.56M
Oct 12, 2026$6.27$6.345$5.77$5.932.54M
Oct 9, 2026$6.05$6.17$6.015$6.041.04M
Oct 8, 2026$6.14$6.1995$6.02$6.041.27M
Oct 7, 2026$6.04$6.33$6.02$6.152.01M
Oct 6, 2026$5.94$6.105$5.825$6.023.05M
Oct 5, 2026$5.73$5.96$5.71$5.891.47M
Oct 2, 2026$5.73$5.865$5.605$5.803.28M
Oct 1, 2026$5.84$5.86$5.65$5.731.45M
Sep 30, 2026$5.83$5.925$5.72$5.831.46M
Sep 29, 2026$5.74$5.80$5.685$5.801.28M
Sep 28, 2026$5.66$5.845$5.595$5.771.51M
Sep 25, 2026$5.66$5.83$5.63$5.691.25M
Sep 24, 2026$5.67$5.78$5.54$5.652.02M
Sep 23, 2026$5.82$5.925$5.67$5.711.82M
Sep 22, 2026$5.755$5.82$5.615$5.811.91M

Latest BHC news

The latest Smart Investors Daily articles mentioning BHC.

Stock researchCompany · Overview

BHC research

Overview

Company profile and research snapshot.

Company profile

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.00
Implied upside
—
Analysts
—
BHC recent ratings
DateFirmRatingTarget
Aug 4, 2026TD COWENHold—
May 1, 2026TRUIST SECURITIESHold—
Apr 30, 2026TRUIST SECURITIESHold—
Apr 30, 2026TD COWENHold—
Apr 29, 2026TD COWENHold—
Open full forecast

News briefing

Generated Oct 20, 2026, 9:04 PM

Why Is BHC Up Today?

Bausch Health Companies gained 1.58% today following announcements of expanded public reimbursement coverage for its antipsychotic medication (Pr)OKEDI across Canada. The news signals growing market access for one of the company's key pharmaceutical products, which could support revenue growth in the psychiatry segment.

    Bottom line: Today's gain reflects modest positive momentum from Bausch Health's expanded Canadian reimbursement for (Pr)OKEDI, a development that improves market access but appears to have been partially anticipated by investors. While this win supports the company's psychiatry franchise and demonstrates regulatory progress, BHC investors should focus on larger catalysts such as profitability improvements, debt reduction, or significant pipeline advances to drive sustained appreciation.

    Yahoo · Oct 19, 2026

    Bausch Health Canada Announces Expanded Public Reimbursement for (Pr)OKEDI® (Risperidone for Extended-Release Injectable Suspension) Across Canada for the Treatment of Schizophrenia

    Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced expanded public reimbursement for PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg, with coverage now available for eligible patients, subject to the applicable reimbursement criteria, through public drug plans in seven provinces and multiple federal drug plans.

    Yahoo · Oct 12, 2026

    Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

    Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduat

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By